Despite radiotherapy (RT) is considered as an indispensable treatment that improves clinical symptoms and survival rates of glioblastoma multiforme (GBM), the overall survival time of GBM based on multimodal treatment synergic with RT is still unsatisfying. Herein, we designed an immunostimulated nanoplatform consisting of MnO2 and cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs) within the poly(N-vinylcaprolactam) nanogels (PVCL-MnO2-CpG NGs) for magnetic resonance imaging (MRI)-guided immuno-activated RT against GBM. In this system, I) CpG ODNs can be protected by PVCL NGs from degradation, which can increase the cellular uptake by immune cells and promote the activation of Toll-like receptor 9 (TLR9) pathway, thus enhance the immune responses to assist the therapeutic efficacy of tumour RT. II) PVCL-MnO2-CpG NGs are able to be dissociated to release Mn2+ in the tumour microenvironment, resulting in excellent T1-weighted tumour MRI along with the activation of cyclic GMP–AMP synthase/stimulator of interferon genes (cGAS/STING) pathway and elevated secretion of type-I interferons (IFN-I) in the downstream. III) MnO2 can also act as nanoenzyme to relieve tumour radioresistance through increasing the reactive oxygen species (ROS) level. Compared with RT alone, combinational immunoradiotherapy remarkably promotes the proportion of cytotoxic T cells (CD3+CD8+) and exhibits systemic therapeutic efficacy. Thus, MnO2 and CpG ODNs-loaded PVCL NGs may serve as a potential theranostic platform for MRI-guided immunostimulated RT of GBM.
文章引用产品列表
-
- EK282
- ELISA试剂盒
Mouse TNF-a ELISA Kit检测试剂盒(酶联免疫吸附法)
- ¥1,600.00 – ¥10,800.00
-
- EK280
- ELISA试剂盒
Mouse IFN-gamma ELISA Kit检测试剂盒(酶联免疫吸附法)
- ¥1,600.00 – ¥10,800.00